Key Points
-
The genomic revolution is transforming clinical medicine — instead of the present model of population risk assessment and empirical treatment, we will move to one of predictive individualized care based on molecular classification and targeted therapy. This review highlights the role of DNA microarrays in developing predictive molecular diagnostics for patients with brain tumours.
-
The molecular events that are crucial for normal development and function are similar between individuals. However, in cancer, genetic and epigenetic alterations result in cascades of deregulated molecular events, which lead to genetically complex, highly individual tumours. Finding consistencies that can be therapeutically exploited is vital for the development of new treatments.
-
Brain cancer is now the leading cause of death from cancer in children under the age of 15 and the second leading cause of death from cancer from age 15 to 34. In adults, brain cancer is proportionately less common than other cancers, yet it accounts for a disproportionate percentage of deaths from cancer.
-
Primary brain tumours arise from the constituent cells of the CNS or their meningeal covering, whereas secondary brain tumours metastasize from a distant site. In 1928, Bailey and Cushing suggested that brain tumours could be classified by their microscopic resemblance to a presumed CNS cell of origin or its developmental precursor. Although recent work shows a more complex pattern, this model has remained a guiding principle for brain tumour classification.
-
New approaches are being developed to specifically target proteins or pathways that are altered in cancer cells. Morphologically identical tumours can be distinct in their mutational patterns, signalling-pathway alterations and gene-expression profiles, and, most importantly, in their response to a range of therapies.
-
Medulloblastomas have distinctive global gene-expression profiles that readily distinguish them from morphological mimics, and DNA microarrays can detect molecular subsets of medulloblastoma cases that differ in survival. Low-grade astrocytomas, oligodendrogliomas and glioblastomas also have distinctive global gene-expression profiles.
-
The fact that DNA microarrays can be used to detect molecular subsets that differ in survival indicates that it will soon be possible to develop gene-based predictors of therapeutic response. DNA microarrays might also facilitate the functional analysis of new anti-cancer compounds and the identification of novel biomarkers and molecular-imaging probes.
-
Cancer cells do not 'invent' new pathways; they use pre-existing pathways in different ways or they combine components of these pathways in a new fashion. By mapping, expanding and refining pathway maps in brain cancer, DNA-microarray studies might provide insight into the connectivity of these pathways in the developing and normally functioning brain.
-
It is possible to imagine a day in the not-too-distant future when serum biomarkers and molecular-imaging probes that are identified by DNA microarrays will be used for screening or early detection. Tumours will undergo microarray analysis to identify pathway alterations that point to the most beneficial therapy, and response to therapy will be monitored using molecular imaging probes and/or serum biomarkers.
Abstract
Primary brain tumours are among the most lethal of all cancers, largely as a result of their lack of responsiveness to current therapy. Numerous new therapies hold great promise for the treatment of patients with brain cancer, but the main challenge is to determine which treatment is most likely to benefit an individual patient. DNA-microarray-based technologies, which allow simultaneous analysis of expression of thousands of genes, have already begun to uncover previously unrecognized patient subsets that differ in their survival. Here, we review the progress made so far in using DNA microarrays to optimize brain cancer therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Slonim, D. K. From patterns to pathways: gene expression data analysis comes of age. Nature Genet. 32 (Suppl.), 502–508 (2002).
Barabasi, A. L. & Oltvai, Z. N. Network biology: understanding the cell's functional organization. Nature Rev. Genet. 5, 101–113 (2004). This paper is an excellent review of the concept of network biology, and describes the quantitative tools that can be used to analyse networks.
Ideker, T. Systems biology 101 — what you need to know. Nature Biotechnol. 22, 473–475 (2004).
Legler, J. M. et al. RESPONSE: re: brain and other central nervous system cancers: recent trends in incidence and mortality. J. Natl Cancer Inst. 92, 77–78 (2000).
Mischel, P. S. & Cloughesy, T. F. Targeted molecular therapy of GBM. Brain Pathol. 13, 52–61 (2003).
Bailey, P. & Cushing, H. A Classification of the Tumors of the Glioma Group on a Histogenic Basis with a Correlated Study of Prognosis (Lippincott, Philadelphia, 1928).
Lu, Q. R. et al. Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Cell 109, 75–86 (2002).
Doetsch, F. The glial identity of neural stem cells. Nature Neurosci. 6, 1127–1134 (2003).
Doetsch, F., Caille, I., Lim, D. A., Garcia-Verdugo, J. M. & Alvarez-Buylla, A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97, 703–716 (1999).
Zhou, Q. & Anderson, D. J. The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification. Cell 109, 61–73 (2002).
Hemmati, H. D. et al. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl Acad. Sci. USA 100, 15178–15183 (2003).
Bachoo, R. M. et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1, 269–277 (2002).
Kleihues, P. et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61, 215–225 (2002).
Holland, E. C. et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nature Genet. 25, 55–57 (2000).
Lee, Y. & McKinnon, P. J. DNA ligase IV suppresses medulloblastoma formation. Cancer Res. 62, 6395–6399 (2002). In this paper, the authors compare the global gene-expression profiles of medulloblastomas that are derived from a set of genetically defined mouse crosses, thereby identifying the contribution of a number of genes, including PTC1, LIG4 and p53 , in the development of medulloblastoma.
Lee, Y. et al. A molecular fingerprint for medulloblastoma. Cancer Res. 63, 5428–5437 (2003).
Weiner, H. L. et al. Induction of medulloblastomas in mice by sonic hedgehog, independent of Gli1. Cancer Res. 62, 6385–6389 (2002).
Rao, G., Pedone, C. A., Coffin, C. M., Holland, E. C. & Fults, D. W. c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. Neoplasia 5, 198–204 (2003).
Rao, G. et al. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 23, 6156–6162 (2004).
Choe, G. et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63, 2742–2746 (2003).
Ermoian, R. P. et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin. Cancer Res. 8, 1100–1106 (2002).
Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489–501 (2002).
Berman, D. M. et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297, 1559–1561 (2002). This paper was crucial in defining the role of the hedgehog pathway in the genesis of medulloblastoma, and in identifying inhibition of the hedgehog pathway as a potential therapy.
Wechsler-Reya, R. & Scott, M. P. The developmental biology of brain tumors. Annu. Rev. Neurosci. 24, 385–428 (2001). This outstanding review highlights the genetic mechanisms that are known to be involved in medulloblastoma, as well as other paediatric brain tumours.
Ramaswamy, S. Translating cancer genomics into clinical oncology. N. Engl. J. Med. 350, 1814–1816 (2004).
Liotta, L. A. et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3, 317–325 (2003).
Lindblad-Toh, K. et al. Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nature Biotechnol. 18, 1001–1005 (2000).
Hoque, M. O., Lee, C. C., Cairns, P., Schoenberg, M. & Sidransky, D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res. 63, 2216–2222 (2003).
Albertson, D. G. & Pinkel, D. Genomic microarrays in human genetic disease and cancer. Hum. Mol. Genet. 12, R145–R152 (2003).
Shi, H. et al. Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 63, 2164–2171 (2003).
Yeakley, J. M. et al. Profiling alternative splicing on fiber-optic arrays. Nature Biotechnol. 20, 353–358 (2002).
Mischel, P. S., Nelson, S. F. & Cloughesy, T. F. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol. Ther. 2, 242–247 (2003). This review provides an overview of the gene-expression and signal-transduction alterations in glioblastoma and suggests potential therapeutic strategies.
Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31–36 (2002).
Sawyers, C. L. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell 1, 13–15 (2002).
Betensky, R. A., Louis, D. N. & Cairncross, J. G. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J. Clin. Oncol. 20, 2495–2499 (2002).
Bianco, R. et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22, 2812–2822 (2003).
Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531–537 (1999).
Armstrong, S. A. et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genet. 30, 41–47 (2002).
Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001).
Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418–8423 (2003).
Ramaswamy, S. et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl Acad. Sci. USA 98, 15149–15154 (2001).
Shia, J. et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am. J. Surg. Pathol. 27, 1407–1417 (2003).
Cardiff, R. D. et al. Validation: the new challenge for pathology. Toxicol. Pathol. 32, 31–39 (2004).
Boorman, G. A. et al. Toxicogenomics, drug discovery, and the pathologist. Toxicol. Pathol. 30, 15–27 (2002).
Dhanasekaran, S. M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822–826 (2001).
Shappell, S. B. et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 64, 2270–2305 (2004).
Lossos, I. S. et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N. Engl. J. Med. 350, 1828–1837 (2004).
Bullinger, L. et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350, 1605–1616 (2004).
Valk, P. J. et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617–1628 (2004).
Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937–1947 (2002).
Glinsky, G. V., Higashiyama, T. & Glinskii, A. B. Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm. Clin. Cancer Res. 10, 2272–2283 (2004).
Glinsky, G. V., Glinskii, A. B., Stephenson, A. J., Hoffman, R. M. & Gerald, W. L. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113, 913–923 (2004).
Hedenfalk, I. et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc. Natl Acad. Sci. USA 100, 2532–2537 (2003).
van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).
Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101, 811–816 (2004).
Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
Pomeroy, S. L. et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436–442 (2002). This important paper showed that medulloblastomas can be readily distinguished from other brain tumours, including morphological mimics, on the basis of gene-expression profiling. It also showed that a relatively small number of genes could accurately predict patient survival and response to therapy.
Fernandez-Teijeiro, A. et al. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J. Clin. Oncol. 22, 994–998 (2004). In a logical continuation of the work described in reference 59, the authors showed that gene-expression data can predict the outcome for patients with medulloblastoma, independent of clinical variables.
MacDonald, T. J. et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nature Genet. 29, 143–152 (2001). In this paper, the authors used cDNA-microarray analysis to identify a potentially crucial and therapeutically targetable pathway that might promote metastasis in medulloblastoma.
Oliver, T. G. et al. Transcriptional profiling of the sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc. Natl Acad. Sci. USA 100, 7331–7336 (2003).
Shai, R. et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22, 4918–2493 (2003).
Rickman, D. S. et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 61, 6885–6891 (2001).
Sallinen, S. L. et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 60, 6617–6622 (2000).
Huang, H. et al. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res. 60, 6868–6874 (2000).
Fuller, G. N. et al. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res. 59, 4228–4232 (1999).
Godard, S. et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 63, 6613–6625 (2003).
Khatua, S. et al. Overexpression of the EGFR/FKBP12/HIF-2α pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res. 63, 1865–1870 (2003).
Nutt, C. L. et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 63, 1602–1607 (2003). This paper showed that cDNA-microarray technology could potentially be used to address diagnostically confusing gliomas, and that transcriptional information contains more data about outcome than does pathological examination.
Mischel, P. S. et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22, 2361–2373 (2003). This paper highlights the potential of cDNA microarrays to detect molecular subsets of morphologically identical glioblastomas.
Freije, W. A. et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. [In the press]. In this paper, the authors demonstrate that gene-expression-based grouping of malignant gliomas is a more powerful predictor of survival than pathological type, grade or age.
Scherf, U. et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet. 24, 236–244 (2000).
Staunton, J. E. et al. Chemosensitivity prediction by transcriptional profiling. Proc. Natl Acad. Sci. USA 98, 10787–10792 (2001).
Wallqvist, A. et al. Mining the NCI screening database: explorations of agents involved in cell cycle regulation. Prog. Cell Cycle Res. 5, 173–179 (2003).
Butte, A. J., Tamayo, P., Slonim, D., Golub, T. R. & Kohane, I. S. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc. Natl Acad. Sci. USA 97, 12182–12186 (2000).
Bohen, S. P. et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc. Natl Acad. Sci. USA 100, 1926–1930 (2003).
Sotiriou, C. et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 4, R3 (2002).
Cheok, M. H. et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nature Genet. 34, 85–90 (2003).
Stegmaier, K. et al. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nature Genet. 36, 257–263 (2004).
Reifenberger, G. & Louis, D. N. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J. Neuropathol. Exp. Neurol. 62, 111–126 (2003).
Gajjar, A. et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J. Clin. Oncol. 22, 984–993 (2004).
Liu, E. T. & Karuturi, K. R. Microarrays and clinical investigations. N. Engl. J. Med. 350, 1595–1597 (2004).
Diehn, M., Eisen, M. B., Botstein, D. & Brown, P. O. Large-scale identification of secreted and membrane-associated gene products using DNA microarrays. Nature Genet. 25, 58–62 (2000).
Tanwar, M. K., Gilbert, M. R. & Holland, E. C. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 62, 4364–4368 (2002).
Herschman, H. R. Molecular imaging: looking at problems, seeing solutions. Science 302, 605–608 (2003).
Bergmann, S., Ihmels, J. & Barkai, N. Similarities and differences in genome-wide expression data of six organisms. PLoS Biol. 2, E9 (2004).
Stuart, J. M., Segal, E., Koller, D. & Kim, S. K. A gene-coexpression network for global discovery of conserved genetic modules. Science 302, 249–255 (2003).
Chang, H. Y. et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2, E7 (2004).
Whitfield, M. L. et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell 13, 1977–2000 (2002).
Ficenec, D. et al. Computational knowledge integration in biopharmaceutical research. Brief. Bioinform. 4, 260–278 (2003).
Buckingham, S. Bioinformatics: programmed for success. Nature 425, 209–215 (2003).
Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
Angelastro, J. M. et al. Identification of diverse nerve growth factor-regulated genes by serial analysis of gene expression (SAGE) profiling. Proc. Natl Acad. Sci. USA 97, 10424–10429 (2000).
Liu, D. X. & Greene, L. A. Regulation of neuronal survival and death by E2F-dependent gene repression and derepression. Neuron 32, 425–438 (2001).
Hartwell, L. H., Hopfield, J. J., Leibler, S. & Murray, A. W. From molecular to modular cell biology. Nature 402 (Suppl.), C47–C52 (1999).
Jeong, H., Tombor, B., Albert, R., Oltvai, Z. N. & Barabasi, A. L. The large-scale organization of metabolic networks. Nature 407, 651–654 (2000).
Alon, U. Biological networks: the tinkerer as an engineer. Science 301, 1866–1867 (2003).
Agrawal, H. Extreme self-organization in networks constructed from gene expression data. Phys. Rev. Lett. 89, 268702 (2002).
Chen, J. et al. The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface. Nucleic Acids Res. 32, D578–D581 (2004).
Ramaswamy, S. & Golub, T. R. DNA microarrays in clinical oncology. J. Clin. Oncol. 20, 1932–1941 (2002).
Acknowledgements
We wish to thank S. Horvath, M. Carlson, W. Freije and Z. Fang for their contribution to this work, and we thank D. Geschwind and H. Kornblum for helpful discussions about this review. The authors are supported by the NINDS and NCI and by Accelerate Brain Cancer Cure, the Packard Foundation, the Harry Allgauer Foundation through The Doris R. Ullmann Fund for Brain Tumor Research Technologies, the Henry E. Singleton Brain Tumor Endowment, Art of the Brain and the Ziering Family Foundation in memory of Sigi Ziering.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Related links
DATABASES
Entrez Gene
FURTHER INFORMATION
Encyclopedia of Life Sciences
Glossary
- GLIOMA
-
Any brain tumour that originates from the glial cell lineage.
- METASTASIS
-
The spread of cancer cells from one organ or tissue to another, usually though the blood stream or the lymphatic system.
- SINGLE NUCLEOTIDE POLYMORPHISMS
-
Bi-allelic (typically) base pair substitutions, which are the most common forms of genetic polymorphism.
- ALTERNATIVE SPLICING
-
During splicing, introns are excised from RNA after transcription and the cut ends are rejoined to form a continuous message. Alternative splicing allows the production of different messages from the same DNA molecule.
- DESMOPLASTIC
-
A term that refers to the growth of dense fibrous tissue around a tumour.
- cDNA
-
Complementary DNA that is produced from an RNA template by an RNA-dependent DNA polymerase.
- CHEMOTAXIS
-
The movement of cells in response to a chemical gradient that is provided by chemotactic agents.
- RT-PCR
-
Reverse transcriptase–polymerase chain reaction (PCR) — a reaction in which messenger RNA is converted into DNA (reverse transcription), which is then amplified by PCR.
Rights and permissions
About this article
Cite this article
Mischel, P., Cloughesy, T. & Nelson, S. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 5, 782–792 (2004). https://doi.org/10.1038/nrn1518
Issue Date:
DOI: https://doi.org/10.1038/nrn1518
This article is cited by
-
Znf179 induces differentiation and growth arrest of human primary glioblastoma multiforme in a p53-dependent cell cycle pathway
Scientific Reports (2017)
-
Comparison of Gene Expression Profile Between Tumor Tissue and Adjacent Non-tumor Tissue in Patients with Gastric Gastrointestinal Stromal Tumor (GIST)
Cell Biochemistry and Biophysics (2015)
-
Improving reliability and absolute quantification of human brain microarray data by filtering and scaling probes using RNA-Seq
BMC Genomics (2014)
-
RETRACTED ARTICLE: Ranking candidate genes of esophageal squamous cell carcinomas based on differentially expressed genes and the topological properties of the co-expression network
European Journal of Medical Research (2014)
-
Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas
Acta Neuropathologica (2011)